[go: up one dir, main page]

WO2001012192A3 - Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil - Google Patents

Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil Download PDF

Info

Publication number
WO2001012192A3
WO2001012192A3 PCT/GB2000/003116 GB0003116W WO0112192A3 WO 2001012192 A3 WO2001012192 A3 WO 2001012192A3 GB 0003116 W GB0003116 W GB 0003116W WO 0112192 A3 WO0112192 A3 WO 0112192A3
Authority
WO
WIPO (PCT)
Prior art keywords
nedocromil
benzothiazolone
aminoethyl
pharmaceutical compositions
disodium cromoglycate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003116
Other languages
French (fr)
Other versions
WO2001012192A2 (en
Inventor
Francis Ince
John Dixon
Philip Ronald Holt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Priority to AU64603/00A priority Critical patent/AU6460300A/en
Publication of WO2001012192A2 publication Critical patent/WO2001012192A2/en
Publication of WO2001012192A3 publication Critical patent/WO2001012192A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a second active ingredient (B) being disodium cromoglycate or nedocromil, for use in the treatment of obstructive airways diseases.
PCT/GB2000/003116 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil Ceased WO2001012192A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64603/00A AU6460300A (en) 1999-08-18 2000-08-14 Pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902938A SE9902938D0 (en) 1999-08-18 1999-08-18 Pharmaceutical compositions
SE9902938-1 1999-08-18

Publications (2)

Publication Number Publication Date
WO2001012192A2 WO2001012192A2 (en) 2001-02-22
WO2001012192A3 true WO2001012192A3 (en) 2001-12-13

Family

ID=20416696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003116 Ceased WO2001012192A2 (en) 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil

Country Status (3)

Country Link
AU (1) AU6460300A (en)
SE (1) SE9902938D0 (en)
WO (1) WO2001012192A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329586T3 (en) 2003-11-21 2009-11-27 Theravance, Inc. COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE BETA2 ADRENERGIC RECEIVER AND ANTAGONIST OF THE MUSCARINE RECEIVER.
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
CN102124003A (en) 2008-06-18 2011-07-13 阿斯利康(瑞典)有限公司 Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GONZALEZ J.P. ET AL: "Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease.", DRUGS, (1987) 34/5 (560-577)., XP000986536 *
LAL S. ET AL: "Nedocromil sodium is more effective than cromolyn sodium for the treatmen of chronic reversible obstructive airway disease.", CHEST, (1993) 104/2 (438-447)., XP000986434 *
LURIE A. ET AL: "Long-term management of reversible obstructive airways disease in adults.", LUNG, (1990) 168/SUPPL. (154-167)., XP000986437 *

Also Published As

Publication number Publication date
SE9902938D0 (en) 1999-08-18
AU6460300A (en) 2001-03-13
WO2001012192A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
EE200300295A (en) A quinuclidine carbamate derivative, its preparation and its use in the preparation of a medicament for the treatment of respiratory, urinary or gastrointestinal diseases, and a pharmaceutical composition containing it.
EE05404B1 (en) A quinuclidine derivative, its preparation and its use in the preparation of a medicament for the treatment of respiratory, urinary or gastrointestinal diseases, and a pharmaceutical composition containing it
EE200000532A (en) Use of pyrimidine derivatives for the preparation of a medicament for the treatment of HIV infection, a compound, a pharmaceutical composition containing it, a process for the preparation of a compound and a composition, and a combination preparation for use in
HUP0400203A3 (en) Use of combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases, for preparation of pharmaceutical compositions
NO20034612L (en) 3,4-di-substituted cyclobutene-1,2-dione, pharmaceutical compositions comprising the compounds, and use of the compounds for the manufacture of medicaments for the treatment of chemokine-mediated diseases
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
EG25542A (en) Oral dosge forms for propiverne or pharmaceutically acceptable salts thereof having prolonged release of the active agent
DE60235719D1 (en) WOMEN'S HYGIENIC PRODUCTS FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
WO2001012167A3 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
AU2002358082A1 (en) Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
WO2001011933A3 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a pde4 inhibitor
WO2001012192A3 (en) Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil
WO2004014293A3 (en) Combination of anti-muscarinic agents and non-glucocorticoid steroids
NO323466B1 (en) New quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives, processes for their preparation, use thereof in medicaments for the treatment of pain, and pharmaceutical compositions comprising such derivatives
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
WO2002069979A3 (en) Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
WO2001012191A3 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid
WO2005009407A3 (en) Oral pharmaceutical formulations of olanzapine
IL162385A (en) Benzothiazole - and benzoxazole - 4,7 - dione derivatives, uses thereof for the preparation of a medicament, medicaments containing them and pharmaceutical compositions containing them
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
WO2003009835A3 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
WO2001028535A3 (en) Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate
IL164240A (en) 1,3,5 - triazine derivatives, compositions comprising them and uses thereof in the manufacture of medicaments for the treatment of parkinson's disease
DE60108354D1 (en) 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09674083

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP